Disease Detection by Ultrasensitive Quantification of Microdosed Synthetic Urinary Biomarkers

The delivery of exogenous agents can enable noninvasive disease monitoring, but existing low-dose approaches require complex infrastructure. In this paper, we describe a microdose-scale injectable formulation of nanoparticles that interrogate the activity of thrombin, a key regulator of clotting, an...

Full description

Bibliographic Details
Main Authors: Gaylord, Shonda T. (Author), Ngan, Kevin C. (Author), Dumont Milutinovic, Milena (Author), Kwong, Gabriel A. (Contributor), Bhatia, Sangeeta N. (Contributor), Walt, David R. (Author), Warren, Andrew David (Contributor)
Other Authors: Harvard University- (Contributor)
Format: Article
Language:English
Published: American Chemical Society (ACS), 2015-11-10T15:08:02Z.
Subjects:
Online Access:Get fulltext
LEADER 02004 am a22003253u 4500
001 99875
042 |a dc 
100 1 0 |a Gaylord, Shonda T.  |e author 
100 1 0 |a Harvard University-  |e contributor 
100 1 0 |a Warren, Andrew David  |e contributor 
100 1 0 |a Kwong, Gabriel A.  |e contributor 
100 1 0 |a Bhatia, Sangeeta N.  |e contributor 
700 1 0 |a Ngan, Kevin C.  |e author 
700 1 0 |a Dumont Milutinovic, Milena  |e author 
700 1 0 |a Kwong, Gabriel A.  |e author 
700 1 0 |a Bhatia, Sangeeta N.  |e author 
700 1 0 |a Walt, David R.  |e author 
700 1 0 |a Warren, Andrew David  |e author 
245 0 0 |a Disease Detection by Ultrasensitive Quantification of Microdosed Synthetic Urinary Biomarkers 
260 |b American Chemical Society (ACS),   |c 2015-11-10T15:08:02Z. 
856 |z Get fulltext  |u http://hdl.handle.net/1721.1/99875 
520 |a The delivery of exogenous agents can enable noninvasive disease monitoring, but existing low-dose approaches require complex infrastructure. In this paper, we describe a microdose-scale injectable formulation of nanoparticles that interrogate the activity of thrombin, a key regulator of clotting, and produce urinary reporters of disease state. We establish a customized single molecule detection assay that enables urinary discrimination of thromboembolic disease in mice using doses of the nanoparticulate diagnostic agents that fall under regulatory guidelines for "microdosing." 
520 |a National Science Foundation (U.S.). Graduate Research Fellowship 
520 |a National Institutes of Health (U.S.) (Ruth L. Kirschstein National Research Service Award F32CA159496-02) 
520 |a Burroughs Wellcome Fund (Career Award at the Scientific Interface) 
520 |a National Cancer Institute (U.S.) (Koch Institute Support (Core) Grant P30-CA14051) 
520 |a David H. Koch Institute for Integrative Cancer Research at MIT (Frontier Research Program) 
546 |a en_US 
655 7 |a Article 
773 |t Journal of the American Chemical Society